IND: (+91) 949418 5556
sales@envisioninteligence.com
- Home
- Industry Reports
- Diagnostics
- Healthcare
- Preventive Vaccines Market – Size, Outlook, Trends and Forecast (2021 – 2027)
Preventative vaccines are administered to a person who is free of the targeted infection. By introducing a part of the virus or an inactive virus (which acts as a decoy) into the body, the immune system reacts by producing antibodies. If years later, the virus enters the organism, these antibodies will recognise and destroy it.
Preventive Vaccines Market Share:
Based on Type of Vaccine, the Preventive Vaccines Market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In 2018, the conjugate segment is expected to account for the most significant share of the vaccines market. The growth in this market is mainly driven by increasing investments by the government of developing countries and rising prevalence of infectious diseases.
Preventive Vaccines Market Size & Growth:
The Preventive Vaccines Market accounted for a market share of USD 34 billion in 2018 and is expected to reach USD 62 billion by 2024.
The Preventive Vaccines Market is segmented into such as North America, South America, Asia-Pacific, Middle East & Africa, and Europe. Among these, North America dominated the overall market in 2018. The country is expected to maintain its bearing in the coming years as it is reserved to acquire a share of XX% in the Preventive Vaccines Market by the end of 2024.
Increasing number of products, Increasing awareness, Increasing investments in R&D Technological advancements, Increasing government-funded projects and associations promoting vaccination, Growing demand in the developing countries (China and India) of the Asia-Pacific region are the primary factors driving the growth of the market.
Preventive Vaccines Market Industry Analysis:
The market has been segmented based on the type of vaccines and application. The segment based on the type of vaccine includes live, attenuated vaccine, inactivated vaccines, subunit vaccine, toxoid vaccines, conjugate vaccines, DNA vaccine, and recombinant vector vaccine. The market segment based on applications has been further subdivided into pediatric vaccine and adult vaccine. The pediatric vaccines include pneumococcal vaccine, varicella vaccine, combination vaccines (Bivalent, trivalent, tetravalent, and pentavalent vaccines), MMR, poliovirus, hepatitis, HIB, and other pediatric vaccines. The segment on adult vaccines includes influenza, cervical cancer, hepatitis, zoster, and other adult vaccines.
Preventive Vaccines Market Outlook:
The vaccines market is different from any other commodity market. Compared to the pharmaceutical market, the vaccines market is relatively small, although growing fast. The vaccines market is instead concentrated on both supply and demand sides. It is highly regulated and largely dependent on public purchasers and donor policies. The vaccines market has very distinct features that increase the complexity of assessing and understanding pricing and procurement in their context. It is made up of individual markets for individual vaccines or vaccine types, each with its specificities, particularly on the supply side.
Preventive Vaccines Market Trends:
- Mitsubishi Tanabe announced that they have entered into a strategic collaboration for the development of an antibody drug to treat neurodegenerative diseases, such as amyotrophic lateral sclerosis.
- Takeda Pharmaceutical Company Limited and Denali Therapeutics announced that they have entered into a strategic option and collaboration agreement to develop and commercialise up to three specified therapeutic product candidates for neurodegenerative diseases.
Preventive Vaccines Market Research report includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Takeda
- Sanofi
- GlaxoSmithKline
- Johnson & Johnson
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.1.1 Huge market demand
4.1.2 Higher profitability and improved technology
4.1.3 Government funded projects and Associations
4.14 Increasing demand, higher onset of diseases
4.2 Restraints
4.2.1 High regulatory intervention and cost
4.2.2 Increasing demand for cost-effective vaccines
4.3 Opportunities
4.3.1 New Target Populations-shift from established markets to lesser developed markets
4.4 Challenges
4.4.1 Difficult in development process
Chapter 5 Market Segmentation, By Type of Vaccine
5.1 Recombinant Vector Vaccines
5.2 DNA Vaccines
5.3 Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 Subunit Vaccines
5.6 Inactivated Vaccines
5.7 Live, Attenuated Vaccines
Chapter 6 Market Segmentation, By Applications
6.1 Pediatric Vaccine
6.1.1 Combinations Vaccines
6.1.1.1 Bivalent Vaccines
6.1.1.2 Trivalent Vaccines
6.1.1.3 Tetravalent Vaccines
6.1.1.4 Pentavalent Vaccines
6.1.2 HIB
6.1.3 Hepatitis
6.1.4 Poliovirus
6.1.5 MMR
6.1.6 Varicella Vaccines
6.1.7 Pneumococcal Vaccines
6.1.8 Others
6.2 Adult Vaccine
6.2.1 Zoster
6.2.2 Hepatitis
6.2.3 Cervical Cancer
6.2.4 Influenza
6.2.5 Others
Chapter 7 Market Segmentation, By Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Mexico
7.1.5 Others
7.2 Europe
7.2.1 Introduction
7.2.2 U.K
7.2.3 Spain
7.2.4 Italy
7.2.5 France
7.2.6 Russia
7.2.7 Others
7.3 Asia-Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 Australia
7.3.6 Others
7.4 South America
7.4.1 Introduction
7.4.2 Brazil
7.4.3 Argentina
7.4.4 Others
7.5 Middle East & Africa
7.5.1 Introduction
7.5.2 South Africa
7.5.3 Others
Chapter 8 Competitive Landscape
8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
8.2 Market Share Analysis
8.3 Strategies Adopted By Top Companies
Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Mitsubishi Tanabe
9.2. AstraZeneca
9.3. Astellas Pharma
9.4. Takeda
9.5. Emergent BioSolutions
9.6. Pfizer
9.7. Sanofi
9.8. GlaxoSmithKline
9.9. Merck & Co.
9.10. Johnson & Johnson
9.11. CSL
9.12. Emergent Biosolutions
9.13. Serum Institute
9.14. MedImmune, LLC
9.15. Bavarian Nordic
Chapter 10 Market Insights
10.1 Insights of Industry Experts
10.2 Analyst Opinion (Market Understanding)
10.3 Investment Opportunities
Chapter 11 Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Global Report
$2,700.00 – $8,100.00
- EUR: €2,271.20 - €6,813.59
- INR: ₹201,715.30 - ₹605,145.90
- AED: د.إ9,909.00 - د.إ29,727.00
- GBP: £1,968.17 - £5,904.52
Additional information
| Report Type | Extensive Report, Miniature report, Snapshot Report |
|---|---|
| Licence | Single User License, Team License, Corporate License |
Preventative vaccines are administered to a person who is free of the targeted infection. By introducing a part of the virus or an inactive virus (which acts as a decoy) into the body, the immune system reacts by producing antibodies. If years later, the virus enters the organism, these antibodies will recognise and destroy it.
Preventive Vaccines Market Share:
Based on Type of Vaccine, the Preventive Vaccines Market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In 2018, the conjugate segment is expected to account for the most significant share of the vaccines market. The growth in this market is mainly driven by increasing investments by the government of developing countries and rising prevalence of infectious diseases.
Preventive Vaccines Market Size & Growth:
The Preventive Vaccines Market accounted for a market share of USD 34 billion in 2018 and is expected to reach USD 62 billion by 2024.
The Preventive Vaccines Market is segmented into such as North America, South America, Asia-Pacific, Middle East & Africa, and Europe. Among these, North America dominated the overall market in 2018. The country is expected to maintain its bearing in the coming years as it is reserved to acquire a share of XX% in the Preventive Vaccines Market by the end of 2024.
Increasing number of products, Increasing awareness, Increasing investments in R&D Technological advancements, Increasing government-funded projects and associations promoting vaccination, Growing demand in the developing countries (China and India) of the Asia-Pacific region are the primary factors driving the growth of the market.
Preventive Vaccines Market Industry Analysis:
The market has been segmented based on the type of vaccines and application. The segment based on the type of vaccine includes live, attenuated vaccine, inactivated vaccines, subunit vaccine, toxoid vaccines, conjugate vaccines, DNA vaccine, and recombinant vector vaccine. The market segment based on applications has been further subdivided into pediatric vaccine and adult vaccine. The pediatric vaccines include pneumococcal vaccine, varicella vaccine, combination vaccines (Bivalent, trivalent, tetravalent, and pentavalent vaccines), MMR, poliovirus, hepatitis, HIB, and other pediatric vaccines. The segment on adult vaccines includes influenza, cervical cancer, hepatitis, zoster, and other adult vaccines.
Preventive Vaccines Market Outlook:
The vaccines market is different from any other commodity market. Compared to the pharmaceutical market, the vaccines market is relatively small, although growing fast. The vaccines market is instead concentrated on both supply and demand sides. It is highly regulated and largely dependent on public purchasers and donor policies. The vaccines market has very distinct features that increase the complexity of assessing and understanding pricing and procurement in their context. It is made up of individual markets for individual vaccines or vaccine types, each with its specificities, particularly on the supply side.
Preventive Vaccines Market Trends:
- Mitsubishi Tanabe announced that they have entered into a strategic collaboration for the development of an antibody drug to treat neurodegenerative diseases, such as amyotrophic lateral sclerosis.
- Takeda Pharmaceutical Company Limited and Denali Therapeutics announced that they have entered into a strategic option and collaboration agreement to develop and commercialise up to three specified therapeutic product candidates for neurodegenerative diseases.
Preventive Vaccines Market Research report includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Takeda
- Sanofi
- GlaxoSmithKline
- Johnson & Johnson
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.1.1 Huge market demand
4.1.2 Higher profitability and improved technology
4.1.3 Government funded projects and Associations
4.14 Increasing demand, higher onset of diseases
4.2 Restraints
4.2.1 High regulatory intervention and cost
4.2.2 Increasing demand for cost-effective vaccines
4.3 Opportunities
4.3.1 New Target Populations-shift from established markets to lesser developed markets
4.4 Challenges
4.4.1 Difficult in development process
Chapter 5 Market Segmentation, By Type of Vaccine
5.1 Recombinant Vector Vaccines
5.2 DNA Vaccines
5.3 Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 Subunit Vaccines
5.6 Inactivated Vaccines
5.7 Live, Attenuated Vaccines
Chapter 6 Market Segmentation, By Applications
6.1 Pediatric Vaccine
6.1.1 Combinations Vaccines
6.1.1.1 Bivalent Vaccines
6.1.1.2 Trivalent Vaccines
6.1.1.3 Tetravalent Vaccines
6.1.1.4 Pentavalent Vaccines
6.1.2 HIB
6.1.3 Hepatitis
6.1.4 Poliovirus
6.1.5 MMR
6.1.6 Varicella Vaccines
6.1.7 Pneumococcal Vaccines
6.1.8 Others
6.2 Adult Vaccine
6.2.1 Zoster
6.2.2 Hepatitis
6.2.3 Cervical Cancer
6.2.4 Influenza
6.2.5 Others
Chapter 7 Market Segmentation, By Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Mexico
7.1.5 Others
7.2 Europe
7.2.1 Introduction
7.2.2 U.K
7.2.3 Spain
7.2.4 Italy
7.2.5 France
7.2.6 Russia
7.2.7 Others
7.3 Asia-Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 Australia
7.3.6 Others
7.4 South America
7.4.1 Introduction
7.4.2 Brazil
7.4.3 Argentina
7.4.4 Others
7.5 Middle East & Africa
7.5.1 Introduction
7.5.2 South Africa
7.5.3 Others
Chapter 8 Competitive Landscape
8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
8.2 Market Share Analysis
8.3 Strategies Adopted By Top Companies
Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Mitsubishi Tanabe
9.2. AstraZeneca
9.3. Astellas Pharma
9.4. Takeda
9.5. Emergent BioSolutions
9.6. Pfizer
9.7. Sanofi
9.8. GlaxoSmithKline
9.9. Merck & Co.
9.10. Johnson & Johnson
9.11. CSL
9.12. Emergent Biosolutions
9.13. Serum Institute
9.14. MedImmune, LLC
9.15. Bavarian Nordic
Chapter 10 Market Insights
10.1 Insights of Industry Experts
10.2 Analyst Opinion (Market Understanding)
10.3 Investment Opportunities
Chapter 11 Appendix
11.1 List of Tables
11.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.
Related Products
Global NGS-based RNA Sequencing Market – Size, Outlook, Trend...
Global Microbiome Sequencing Services Market – Size, Outlook,...
Global Health Insurance Exchange Market – Size, Outlook, Tren...
Global Terahertz And Infrared Spectroscopy Market – Size, Out...